Another weight loss drug goes into shortage

High demand has pushed another Novo Nordisk weight loss drug into shortage.

Advertisement

Saxenda (liraglutide) 6 milligram/milliliter, 3 milliliter solutions will be in limited supply for the rest of 2023, according to a July 18 FDA post. 

Some solutions of Novo Nordisk’s other chronic weight management drug, Wegovy (semaglutide), have been in shortage for more than a year because of high demand. In May, the drugmaker curbed its output of lower dose strengths to ensure and meet drug quality standards. 

The company estimated the Wegovy shortage will recover in October. 

Ozempic, a Novo Nordisk Type 2 diabetes drug popular for its off-label use for weight loss, has also experienced unsteady supply levels for months.

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Pharmacy

Advertisement

Comments are closed.